Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study
Open Access
- 8 November 2018
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 119 (11), 1326-1331
- https://doi.org/10.1038/s41416-018-0307-3
Abstract
Cytidine deaminase (CDA) plays a crucial role in the degradation of gemcitabine. In our previous retrospective study, CDA enzymatic activity was the strongest prognostic biomarker of the activity and efficacy of platinum/gemcitabine combinations. The aim of this prospective study was to validate the prognostic role of CDA activity in the first-line treatment of advanced non-small-cell lung cancer. A total of 124 untreated patients received standard doses of platinum/gemcitabine. CDA activity was baseline measured in plasma samples by spectrophotometric assay. Using the median CDA level as cut-off, in the patients with high versus low CDA activity the response rate was 25.0% (95% CI, 14.7–37.8) and 54.1% (95% CI, 40.8–66.9), P = 0.0013; the 6-month progression rate was 34.5% (95% CI, 22.6–46.6) and 54.1% (95% CI, 40.9–65.6), HR = 2.01 (95% CI, 1.32–3.06), P < 0.001; the 1-year survival rate was 23.3% (95% CI, 13.6–34.6) and 57.3% (95% CI, 43.9–68.6), HR = 2.20 (95% CI, 1.46–3.34), P = 0.0002, respectively. CDA activity resulted to be an independent prognostic factor for progression and survival at multivariate analysis. This study validated prospectively the prognostic role of the CDA activity and should prompt larger and adequately designed randomised prospective studies to establish the predictive impact of this test in improving the outcome of selected patients.Funding Information
- Associazione Donne Contro il Cancro al Polmone (AIDA CP Onlus). No grant numbers are applicable.
This publication has 19 references indexed in Scilit:
- Randomized International Phase III Trial of ERCC1 and RRM1 Expression–Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2013
- Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patientsAnnals of Oncology, 2011
- Integrating pharmacogenetics into gemcitabine dosing—time for a change?Nature Reviews Clinical Oncology, 2011
- Cytidine Deaminase Residual Activity in Serum Is a Predictive Marker of Early Severe Toxicities in Adults After Gemcitabine-Based ChemotherapiesJournal of Clinical Oncology, 2010
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer PatientsClinical Cancer Research, 2008
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- An application of changepoint methods in studying the effect of age on survival in breast cancerComputational Statistics & Data Analysis, 1999
- Increased serum cytidine deaminase activity in gout and articular chondrocalcinosis.Annals Of The Rheumatic Diseases, 1991
- Cytidine deaminase activity as a measure of acute inflammation in rheumatoid arthritis.Annals Of The Rheumatic Diseases, 1986